CN117137136A - 一种具有减脂功能的组合物及其制备方法和应用 - Google Patents
一种具有减脂功能的组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN117137136A CN117137136A CN202311014140.XA CN202311014140A CN117137136A CN 117137136 A CN117137136 A CN 117137136A CN 202311014140 A CN202311014140 A CN 202311014140A CN 117137136 A CN117137136 A CN 117137136A
- Authority
- CN
- China
- Prior art keywords
- composition
- powder
- lipid
- parts
- green tea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 230000001603 reducing effect Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 244000269722 Thea sinensis Species 0.000 claims abstract description 78
- 239000000843 powder Substances 0.000 claims abstract description 72
- 235000009569 green tea Nutrition 0.000 claims abstract description 55
- 240000000249 Morus alba Species 0.000 claims abstract description 49
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 49
- 230000000694 effects Effects 0.000 claims abstract description 36
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 34
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 34
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 34
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 34
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 34
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 34
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000013616 tea Nutrition 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- 230000001580 bacterial effect Effects 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 15
- 235000013824 polyphenols Nutrition 0.000 claims description 15
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 239000011812 mixed powder Substances 0.000 claims description 7
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 6
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 6
- 229940026510 theanine Drugs 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 claims description 3
- 241000167854 Bourreria succulenta Species 0.000 claims description 3
- 240000000560 Citrus x paradisi Species 0.000 claims description 3
- 240000003394 Malpighia glabra Species 0.000 claims description 3
- 235000014837 Malpighia glabra Nutrition 0.000 claims description 3
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 239000003524 antilipemic agent Substances 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 235000019693 cherries Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- 229920000294 Resistant starch Polymers 0.000 claims description 2
- 240000007651 Rubus glaucus Species 0.000 claims description 2
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 2
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 2
- 235000004634 cranberry Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
- 229960000511 lactulose Drugs 0.000 claims description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 235000021254 resistant starch Nutrition 0.000 claims description 2
- 229940075430 wheat dextrin Drugs 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 abstract description 39
- 235000018291 probiotics Nutrition 0.000 abstract description 39
- 230000000529 probiotic effect Effects 0.000 abstract description 15
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101000876418 Homo sapiens Laforin Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102100035192 Laforin Human genes 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 235000020610 powder formula Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有减脂功能的组合物及其制备方法和应用,所述具有减脂功能的组合物包括下述重量份的原料,桑抹茶粉1‑15份、干酪乳杆菌1‑10份、植物乳杆菌1‑10份、益生元75‑85份、果粉5‑15份。本发明的有益效果为:本发明所述具有减脂功能的组合物具有低水活度、高菌活性的优点。同时,桑抹茶和益生菌各自具有减脂的功能,桑抹茶益生菌组合物的减脂功能效果优于单纯补充同量桑抹茶或益生菌的效果。本发明所述的桑抹茶益生菌组合物制备方法可以有效降低组合物的水活度,从而提高其中益生菌的储藏稳定性。
Description
技术领域
本发明属于功能性食品领域,具体涉及一种具有减脂功能的组合物及其制备方法和应用。
背景技术
早在1997年,肥胖就已经被世界卫生组织(world health organization,WHO)正式定义为一种慢性代谢性疾病,其典型特征表现为脂肪组织的增大和体重的增加。随着全球经济的发展和进步,人们的生活水平及日常饮食有了较大的改善和提高,这也导致了肥胖在全球范围内呈现爆发性流行趋势。
肥胖是由于能量代谢长期失调,即能量摄入过多和/或能量消耗不足导致的脂肪沉积增多。针对能量代谢长期失调导致肥胖,以及一系列代谢紊乱症的问题,目前没有一个行之有效的解决方案。主要还是通过减肥来解决,但是常用的减肥方法主要是运动减肥和药物减肥,运动减肥需要的时间长,效果不明确,且对于大多数人来说不易坚持,而药物减肥虽然效果明显,但是长期服用影响人体健康,且停药后易反弹。
益生菌发酵抹茶饮料是目前常见的具有减肥功能的抹茶结合益生菌形式,益生菌发酵通过破环茶多酚与糖苷键使得形成小分子茶多酚,利于茶多酚的吸收,但经过发酵的抹茶饮料因茶多酚多数以游离形式存在,增加了饮料的苦涩味,导致口感差,且在生产过程中对饮料的质量控制难度大,增加了生产成本。
发明内容
本发明的目的为提供一种比例搭配科学均衡,具有减脂功能,且具有高稳定性的减脂功能的组合物及其制备方法和应用。
为实现本发明的上述目的,本发明采用以下技术方案:
一种具有减脂功能的组合物,包括下述重量份的原料,桑抹茶粉1-15份、干酪乳杆菌1-10份、植物乳杆菌1-10份、益生元75-85份、果粉5-15份。
上述一种具有减脂功能的组合物,作为一种优选的实施方案,所述桑抹茶粉中桑叶与抹茶的质量比为1:5-5:1;优选地,所述抹茶中茶氨酸的含量为0.5%-3.0%,茶多酚的含量为10%-18%;更优选地,所述桑叶中DNJ的含量为0.15%-0.33%。
抹茶是以覆盖栽培的茶树鲜叶为原料,鲜叶采摘后经蒸汽(或热风)杀青后干燥,再经研磨工艺加工而成的微粉状产品。抹茶中富含维生素、茶多酚、生物碱、多糖、氨基酸、香气和挥发性成分等物质。其中,茶多酚具有预防肥胖和减脂的作用,主要通过改善肠道微生物群,抑制胰脂肪酶活性、促进膳食脂肪的氧化、减少机体对外源性脂类的吸收、增加***量及能量输出,抑制脂肪生成相关基因的表达、促进脂肪分解及能量代谢相关基因的表达,并通过提高高密度脂蛋白水平和自身抗氧化作用减少脂类沉积,进而达到减肥降脂的效果。
桑抹茶是抹茶和桑叶经科学配比后,用抹茶工艺制成的微粉状配方抹茶,成品翠绿持久,粉质细腻,滋味清雅,从味道和口感都与常规抹茶有较大的区别。桑叶中含有一种独特的天然生物碱1-脱氧野尻霉素(DNJ),研究发现DNJ是一种强效的糖代谢酶抑制剂(比如α-葡萄糖苷酶、己糖激酶、葡萄糖醛酸酶和糖原磷酸酶等),DNJ可显著延缓多糖的降解过程,可降低餐后血糖的峰值,稳定空腹血糖。研究发现桑抹茶还能够有效防止血清总胆固醇、甘油三酯和低密度脂蛋白的升高,并有效增加高密度脂蛋白的含量,桑抹茶有比较明显的降血脂的效果。
益生菌可以促进多酚物质的吸收,从而提高多酚的生物利用度。而益生菌不仅可以改善葡萄糖和脂肪代谢水平,同时也能调节由高脂肪进食造成的肝脏功能紊乱问题,进而改善胰岛素敏感性以及脂肪变性症状,帮助体重减轻。益生菌还能够有效增加胃肠激素,减少胃饥饿素的分泌水平,有效抑制胃肠动力,增加饱腹感,降低体重和脂肪的蓄积。
上述一种具有减脂功能的组合物,作为一种优选的实施方案,所述干酪乳杆菌为干酪乳杆菌Zhang,优选地,所述干酪乳杆菌Zhang的活菌量为1×109CFU/g-10×109CFU/g。
干酪乳杆菌Zhang可以减少高脂饮食导致的肥胖及脂肪堆积,可显著降低甘油三酯和低密度脂蛋白含量,并通过影响肝脏中的基因表达来调节高胆固醇血症大鼠的脂质代谢。
上述一种具有减脂功能的组合物,作为一种优选的实施方案,所述植物乳杆菌为植物乳杆菌P-8,所述植物乳杆菌P-8的活菌量为1×109CFU/g-10×109CFU/g。
植物乳杆菌P-8可以显著减低血清和肝脏中的总胆固醇、甘油三酯和低密度脂蛋白胆固醇含量,而显著增加高密度脂蛋白胆固醇含量,具有良好的降血脂作用。除此之外,低浓度的茶多酚可以促进益生菌的生长,提高益生菌的稳定性。
上述一种具有减脂功能的组合物,作为一种优选的实施方案,所述益生元为低聚果糖、抗性糊精、聚葡萄糖、赤藓糖醇、低聚半乳糖、菊粉、乳果糖、抗性淀粉、低聚木糖、小麦糊精中的至少一种;优选地,所述果粉为针叶樱桃粉、蓝莓粉、柳橙粉、蔓越莓粉、草莓粉、树莓粉、葡萄粉、西柚粉中的至少一种。
本申请的第二方面,提供一种具有减脂功能的组合物的制备方法,包括以下步骤:
(1)将桑抹茶粉、益生元和果粉分别进行干燥;
(2)将干酪乳杆菌、植物乳杆菌和干燥后的益生元进行预混;
(3将步骤(2)所得混合粉与桑抹茶粉、果粉混合均匀,得具有减脂功能的组合物。
上述一种具有减脂功能的组合物的制备方法,作为一种优选的实施方案,步骤(1)中,将桑抹茶粉、益生元和果粉分别干燥至水活度(Aw)≤0.1;优选地,步骤(2)中,预混的转速为10-15r/min,预混的时间为10-15min。
上述一种具有减脂功能的组合物的制备方法,作为一种优选的实施方案,步骤(3)中,混合的转速为10-15r/min,混合时间为30-60min;优选地,所得具有减脂功能的组合物的水活度(Aw)≤0.1。
本申请的第三方面,提供一种权利要求1-5任一项所述具有减脂功能的组合物或权利要求6-8任一制备方法所得具有减脂功能的组合物在减脂保健品、减脂药物方面的应用。
上述所述的应用,作为一种优选的实施方案,所述减脂药物包括药学上可接受的载体或赋形剂;优选地,所述减脂药物可为粉剂、颗粒剂、片剂或胶囊剂。
本发明的有益效果为:本发明所述具有减脂功能的组合物具有低水活度、高菌活性的优点。同时,桑抹茶和益生菌各自具有减脂的功能,桑抹茶益生菌组合物的减脂功能效果优于单纯补充同量桑抹茶或益生菌的效果。本发明所述的桑抹茶益生菌组合物制备方法可以有效降低组合物的水活度,从而提高其中益生菌的储藏稳定性。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施例仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。
实施例1
一种具有减脂功能的组合物,包括下述重量份的原料,桑抹茶粉10份、干酪乳杆菌5份、植物乳杆菌5份、益生元80份、针叶樱桃粉10份;
所述桑抹茶粉中桑叶与抹茶的质量比为7:3,所述抹茶中茶氨酸的含量为2.0%,茶多酚的含量为13%;所述桑叶中DNJ的含量为0.26%;
所述干酪乳杆菌为干酪乳杆菌Zhang,且所述干酪乳杆菌Zhang的活菌量为5×109CFU/g,所述植物乳杆菌为植物乳杆菌P-8,所述植物乳杆菌P-8的活菌量为5×109CFU/g;
所述益生元包括低聚果糖40份、低聚半乳糖20份、低聚木糖20份。
实施例1所述一种具有减脂功能的组合物的制备方法,包括以下步骤:
(1)将桑抹茶粉、益生元和果粉分别干燥至水活度(Aw)≤0.1;
(2)将干酪乳杆菌、植物乳杆菌和干燥后的益生元在预混转速为15r/min的条件下预混10min;
(3)将步骤(2)所得混合粉与桑抹茶粉、果粉在转速为10r/min的条件下混合30min,得水活度(Aw)≤0.1的具有减脂功能的组合物。
实施例2
一种具有减脂功能的组合物,包括下述重量份的原料,桑抹茶粉8份、干酪乳杆菌5份、植物乳杆菌10份、益生元75份、葡萄粉15份;
所述桑抹茶粉中桑叶与抹茶的质量比为7:3,所述抹茶中茶氨酸的含量为1.0%,茶多酚的含量为16%;所述桑叶中DNJ的含量为0.26%;
所述干酪乳杆菌为干酪乳杆菌Zhang,且所述干酪乳杆菌Zhang的活菌量为5×109CFU/g,所述植物乳杆菌为植物乳杆菌P-8,所述植物乳杆菌P-8的活菌量为1×109CFU/g;
所述益生元包括低聚果糖40份、低聚半乳糖20份、低聚木糖15份。
实施例2所述一种具有减脂功能的组合物的制备方法,包括以下步骤:
(1)将桑抹茶粉、益生元和果粉分别干燥至水活度(Aw)≤0.1;
(2)将干酪乳杆菌、植物乳杆菌和干燥后的益生元在预混转速为10r/min的条件下预混15min;
(3)将步骤(2)所得混合粉与桑抹茶粉、果粉在转速为10r/min的条件下混合40min,得水活度(Aw)≤0.1的具有减脂功能的组合物。
向实施例2所述具有减脂功能的组合物中加入蒸馏水制成“手捏成团,压之即散”的软材,再以挤压方式通过14~22目筛网(板),制成均匀的颗粒,控制一定的温度,37℃进行干燥,使水活度(Aw)≤0.1,干燥粒冷却后须再过筛,使颗粒均匀,即得颗粒剂成品。
实施例3
一种具有减脂功能的组合物,包括下述重量份的原料,桑抹茶粉5份、干酪乳杆菌7份、植物乳杆菌8份、益生元75份、西柚粉15份;
所述桑抹茶粉中桑叶与抹茶的质量比为7:3,所述抹茶中茶氨酸的含量为1.0%,茶多酚的含量为16%;所述桑叶中DNJ的含量为0.26%;
所述干酪乳杆菌为干酪乳杆菌Zhang,且所述干酪乳杆菌Zhang的活菌量为7×109CFU/g,所述植物乳杆菌为植物乳杆菌P-8,所述植物乳杆菌P-8的活菌量为8×109CFU/g;
所述益生元包括低聚果糖35份、低聚半乳糖25份、低聚木糖15份。
实施例3所述一种具有减脂功能的组合物的制备方法,包括以下步骤:
(1)将桑抹茶粉、益生元和果粉分别干燥至水活度(Aw)≤0.1;
(2)将干酪乳杆菌、植物乳杆菌和干燥后的益生元在预混转速为15r/min的条件下预混10min;
(3)将步骤(2)所得混合粉与桑抹茶粉、果粉在转速为10r/min的条件下混合30min,得水活度(Aw)≤0.1的具有减脂功能的组合物。
向实施例3的桑抹茶益生菌组合物加入蒸馏水制成“手捏成团,压之即散”的软材,再以挤压方式通过14~22目筛网(板),制成均匀的颗粒,控制一定的温度,37℃进行干燥,使水活度(Aw)≤0.1,干燥粒冷却后须再过筛,制得颗粒。空胶囊的制备按照常规方法制得,再将上述颗粒用机械填充法进行硬胶囊填充,最后对胶囊剂进行封口,即制得硬胶囊剂成品。
实施例4
一种具有减脂功能的组合物,包括下述重量份的原料,桑抹茶粉7份、干酪乳杆菌10份、植物乳杆菌5份、益生元76份、蓝莓粉14份;
所述桑抹茶粉中桑叶与抹茶的质量比为7:3,所述抹茶中茶氨酸的含量为1.0%,茶多酚的含量为16%;所述桑叶中DNJ的含量为0.26%;
所述干酪乳杆菌为干酪乳杆菌Zhang,且所述干酪乳杆菌Zhang的活菌量为1×1010CFU/g,所述植物乳杆菌为植物乳杆菌P-8,所述植物乳杆菌P-8的活菌量为5×109CFU/g;
所述益生元包括低聚果糖40份、低聚半乳糖20份、低聚木糖16份。
实施例4所述一种具有减脂功能的组合物的制备方法,包括以下步骤:
(1)将桑抹茶粉、益生元和果粉分别干燥至水活度(Aw)≤0.1;
(2)将干酪乳杆菌、植物乳杆菌和干燥后的益生元在预混转速为15r/min的条件下预混10min;
(3)将步骤(2)所得混合粉与桑抹茶粉、果粉在转速为10r/min的条件下混合30min,得水活度(Aw)≤0.1的具有减脂功能的组合物。
将实施例4的桑抹茶益生菌组合物与硬脂酸镁充分混匀,加入蒸馏水进行湿法造粒,之后对颗粒进行干燥,使水活度(Aw)≤0.1,压片成型,即制得片剂成品。
对比例1
对比例1所述具有减脂功能的组合物与实施例1所述组合物的不同之处在于:
对比例1所述具有减脂功能的组合物的制备方法为:
(1)将干酪乳杆菌、植物乳杆菌和益生元在预混转速为15r/min的条件下预混10min;
(2)将预混合粉与桑抹茶粉、果粉在转速为10r/min的条件下混合30min,得具有减脂功能的组合物。
1、本申请所述具有减脂功能的组合物的水活度测定
测定实施例1-4和对比例1成品的水活度,测试结果如表1所示:
表1
组别 | 水活度(Aw) |
实施例1 | 0.06±0.01 |
实施例2 | 0.06±0.01 |
实施例3 | 0.06±0.01 |
实施例4 | 0.07±0.01 |
对比例1 | 0.36±0.07 |
从表1中可以看出:对比例1中桑抹茶益生菌组合物在制备过程中未将桑抹茶粉、益生元和果粉干燥至水活度(Aw)≤0.1,且未控制总混合粉的水活度(Aw)≤0.1,此时制得的桑抹茶益生菌组合物的水活度(Aw)达到0.36,不利于益生菌的长期储藏稳定性。实施例1-4桑抹茶益生菌组合物的水活度均小0.1,有利于益生菌保持活性,从而提高益生菌在桑抹茶益生菌组合物中的稳定性。
2、本申请所述具有减脂功能的组合物中益生菌的稳定性测定
取实施例1-4和对比1的样品置于恒温恒湿箱(温25℃,湿度75%)中进行储藏加速试验。根据国标《GB 4789.35-2016》每15天检测一次干酪乳杆菌Zhan和植物乳杆P-8的总活菌数,检测结果如表2所示:
表2
组别 | 0天 | 15天 | 30天 | 45天 | 60天 | 75天 | 90天 |
实施例1 | 10×109 | 10×109 | 9.8×109 | 9.8×109 | 9.7×109 | 9.6×109 | 9.6×109 |
实施例2 | 16×109 | 15.9×109 | 15.8×109 | 15.8×109 | 15.7×109 | 15.7×109 | 15.6×109 |
实施例3 | 15×109 | 14.9×109 | 14.9×109 | 14.8×109 | 14.8×109 | 14.7×109 | 14.6×109 |
实施例4 | 15×109 | 15×109 | 14.9×109 | 14.8×109 | 14.8×109 | 14.7×109 | 14.7×109 |
对比例1 | 10×109 | 9.5×109 | 9.1×109 | 8.7×109 | 8.3×109 | 8.0×109 | 7.7×109 |
从表2可以看出:在加速试验的9天里,对比例1样品中的益生菌活菌数出现明显的下降,而实施1-4样品中的益生菌总活菌数没有显著的变化,即本申请所述具有减脂功能的组合物具有高益生菌稳定性。
3、本申请所述具有减脂功能的组合物的减脂效果研究
3.1.实验材料
桑抹茶、益生菌和实施例1所得具有减脂功能的组合物
3.2.动物实验模型建立
选用8周龄雄性C57BL/6小鼠,置于12L:12D的光周期条件下饲喂一周以上,从而适应动物中心环境。
适应一周后将小鼠随机分成五组,每组各10只小鼠,其中实验组三组分别标记为A、B、C组,实验对照组一组标记为D组,空白对照组一组标记为E组,分别对这五组小鼠进行饲喂。
A组:灌胃实施例1制得的样品和饮用水,同时以高脂饲料饲喂小鼠;
B组:灌胃与实施例1制得的样品中所含的桑抹茶等量的桑抹茶折算成一定量的不含益生菌的组合物和饮用水,同时以等量的高脂饲料饲喂小鼠;
C组:灌胃与实施例1制得的样品中所含的益生菌等量的益生菌折算成一定量的不含桑抹茶的组合物和饮用水,同时以等量高脂饲料饲喂小鼠;
D组:灌胃与实验组等体积的饮用水,同时以等量高脂饲料饲喂小鼠作为实验对照;
E组:灌胃与实验组等体积的饮用水,同时以等量普通饲料饲喂小鼠作为空白对照。
小鼠饲喂8周后,称取各组小鼠的体重并记录,眼球取血后处死小鼠,测定小鼠血液的总胆固醇(CHOL),测试结果如表3所示。
表3各组样品对小鼠体重的影响(单位:g)
组别 | 初始 | 第8周 |
A组 | 20.7±0.9 | 34.9±2.5 |
B组 | 19.8±0.4 | 37.6±2.3 |
C组 | 20.1±0.5 | 39.4±2.1 |
D组 | 19.7±0.4 | 42.2±3.2 |
E组 | 19.9±0.6 | 30.1±2.2 |
从表3可以看出:在灌胃不同样品8周后,A组小鼠体重平均增长约14.2g,B组小鼠体重平均增长约17.8g,C组小鼠体重平均增长约19.3g,D组小鼠体重平均增长约22.5g,E组小鼠体重平均增长约10.2g,结果说明桑抹茶和益生菌各自都可以控制小鼠体重的增长,且桑抹茶益生菌组合物的效果优于单纯补充同量桑抹茶或益生菌的效果。
表4各组样品对小鼠血液总胆固醇的影响(单位:mmol/L)
组别 | CHOL |
A组 | 2.67±0.21 |
B组 | 3.38±0.23 |
C组 | 3.52±0.31 |
D组 | 3.96±0.29 |
E组 | 2.12±0.26 |
从表4可以看出:A、B、C组小鼠血液中的总胆固醇浓度均明显低于D组,说明桑抹茶和益生菌各自都可以降低小鼠血液的总胆固醇,且桑抹茶益生菌组合物的效果优于单纯补充同量桑抹茶或益生菌的效果。
以上所述仅为本申请的优选实施例而已,并不用于限制本申请,对于本领域的技术人员来说,本申请可以有各种更改和变化。凡在本申请的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本申请的保护范围之内。
Claims (10)
1.一种具有减脂功能的组合物,其特征在于,包括下述重量份的原料,桑抹茶粉1-15份、干酪乳杆菌1-10份、植物乳杆菌1-10份、益生元75-85份、果粉5-15份。
2.根据权利要求1所述一种具有减脂功能的组合物,其特征在于,所述桑抹茶粉中桑叶与抹茶的质量比为1:5-5:1;优选地,所述抹茶中茶氨酸的含量为0.5%-3.0%,茶多酚的含量为10%-18%;更优选地,所述桑叶中DNJ的含量为0.15%-0.33%。
3.根据权利要求1所述一种具有减脂功能的组合物,其特征在于,所述干酪乳杆菌为干酪乳杆菌Zhang,优选地,所述干酪乳杆菌Zhang的活菌量为1×109CFU/g-10×109CFU/g。
4.根据权利要求1所述一种具有减脂功能的组合物,其特征在于,所述植物乳杆菌为植物乳杆菌P-8,所述植物乳杆菌P-8的活菌量为1×109CFU/g-10×109CFU/g。
5.根据权利要求1所述一种具有减脂功能的组合物,其特征在于,所述益生元为低聚果糖、抗性糊精、聚葡萄糖、赤藓糖醇、低聚半乳糖、菊粉、乳果糖、抗性淀粉、低聚木糖、小麦糊精中的至少一种;优选地,所述果粉为针叶樱桃粉、蓝莓粉、柳橙粉、蔓越莓粉、草莓粉、树莓粉、葡萄粉、西柚粉中的至少一种。
6.权利要求1-5任一项所述具有减脂功能的组合物的制备方法,其特征在于,包括以下步骤:
(1)将桑抹茶粉、益生元和果粉分别进行干燥;
(2)将干酪乳杆菌、植物乳杆菌和干燥后的益生元进行预混;
(3)将步骤(2)所得混合粉与桑抹茶粉、果粉混合均匀,得具有减脂功能的组合物。
7.根据权利要求6所述具有减脂功能的组合物的制备方法,其特征在于,步骤(1)中,将桑抹茶粉、益生元和果粉分别干燥至水活度(Aw)≤0.1;优选地,步骤(2)中,预混的转速为10-15r/min,预混的时间为10-15min。
8.根据权利要求6所述具有减脂功能的组合物的制备方法,其特征在于,步骤(3)中,混合的转速为10-15r/min,混合时间为30-60min;优选地,所得具有减脂功能的组合物的水活度(Aw)≤0.1。
9.权利要求1-5任一项所述具有减脂功能的组合物或权利要求6-8任一制备方法所得具有减脂功能的组合物在减脂保健品、减脂药物方面的应用。
10.根据权利要求9所述的应用,其特征在于,所述减脂药物包括药学上可接受的载体或赋形剂;优选地,所述减脂药物可为粉剂、颗粒剂、片剂或胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311014140.XA CN117137136A (zh) | 2023-08-14 | 2023-08-14 | 一种具有减脂功能的组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311014140.XA CN117137136A (zh) | 2023-08-14 | 2023-08-14 | 一种具有减脂功能的组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117137136A true CN117137136A (zh) | 2023-12-01 |
Family
ID=88901788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311014140.XA Pending CN117137136A (zh) | 2023-08-14 | 2023-08-14 | 一种具有减脂功能的组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117137136A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117547025A (zh) * | 2024-01-12 | 2024-02-13 | 北京新浠芮生物技术有限公司 | 一种控制体重的组合物及其制备方法和应用 |
-
2023
- 2023-08-14 CN CN202311014140.XA patent/CN117137136A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117547025A (zh) * | 2024-01-12 | 2024-02-13 | 北京新浠芮生物技术有限公司 | 一种控制体重的组合物及其制备方法和应用 |
CN117547025B (zh) * | 2024-01-12 | 2024-04-26 | 北京新浠芮生物技术有限公司 | 一种控制体重的组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106954847A (zh) | 具有润肠通便功能的酵素益生菌组合物、应用及加工制剂 | |
CN109628358A (zh) | 一种复合益生菌及其应用 | |
CN117137136A (zh) | 一种具有减脂功能的组合物及其制备方法和应用 | |
EP2401925B1 (fr) | Produit prebiotique et procede de fabrication | |
CN108541951A (zh) | 一种预防老年痴呆、增强记忆力的合生元组合物及其制剂 | |
CN104664370A (zh) | 一种亚麻咀嚼片 | |
CN111296711A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN112544846A (zh) | 一种益生菌口溶性直饮粉剂及制备方法 | |
CN113974043A (zh) | 一种益生元固体饮料及其制备方法 | |
EP2233015B1 (fr) | Composition symbiotique et son procédé de fabrication | |
CN105685972A (zh) | 具有减脂瘦身功能的益生菌组合物及其制备方法与应用 | |
CN115671132B (zh) | 一种益生菌和益生元的组合物及其应用 | |
CN110710660A (zh) | 含有苦瓜粉的降低血糖组合物及膳食补充剂 | |
CN106389904A (zh) | 六神曲及其制备方法 | |
KR101884634B1 (ko) | 체중 조절 효과를 지닌 유산균 발효액 | |
KR20040037011A (ko) | 유산균 함유 식품조성물 및 그 제조방법 | |
CN110679949A (zh) | 一种减肥组合物及其制备方法 | |
CN107149005B (zh) | 一种红茶菌戊聚糖奶片的制备方法 | |
CN113288997B (zh) | 一种具有减重降糖作用的组合物、制剂及其应用 | |
KR102165106B1 (ko) | 황칠 추출물이 함유된 변비 질환 개선용 환제 또는 과립제 및 그 제조방법. | |
CN112616987A (zh) | 一种黑枸杞参精片压片糖果及其制备方法 | |
CN111466579A (zh) | 一种益生菌菊粉片剂及其制备方法 | |
CN111991521A (zh) | 一种降三高茶含片及其制备方法 | |
CN111264739A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN112430277B (zh) | 菊粉提取方法和包含菊粉的益生菌产品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |